Explore the vast range of titles available.

Melanopsin (opsin4; Opn4), a non-image-forming opsin, has been linked to a number of behavioral responses to light, including circadian photo-entrainment, light suppression of activity in nocturnal animals, and alertness in diurnal animals. We report a physiological role for Opn4 in regulating blood vessel function, particularly in the context of photorelaxation. Using PCR, we demonstrate that Opn4 (a classic G protein-coupled receptor) is expressed in blood vessels. Force-tension myography demonstrates that vessels from Opn4 ⁻/⁻ mice fail to display photorelaxation, which is also inhibited by an Opn4-specific small-molecule inhibitor. The vasorelaxation is wavelength-specific, with a maximal response at ∼430–460 nm. Photorelaxation does not involve endothelial-, nitric oxide-, carbon monoxide-, or cytochrome p450-derived vasoactive prostanoid signaling but is associated with vascular hyperpolarization, as shown by intracellular membrane potential measurements. Signaling is both soluble guanylyl cyclase- and phosphodiesterase 6-dependent but protein kinase G-independent. β-Adrenergic receptor kinase 1 (βARK 1 or GRK2) mediates desensitization of photorelaxation, which is greatly reduced by GRK2 inhibitors. Blue light (455 nM) regulates tail artery vasoreactivity ex vivo and tail blood blood flow in vivo, supporting a potential physiological role for this signaling system. This endogenous opsin-mediated, light-activated molecular switch for vasorelaxation might be harnessed for therapy in diseases in which altered vasoreactivity is a significant pathophysiologic contributor. Significance Non–image-forming opsins such as Opn4 regulate important physiological functions such as circadian photo-entrainment and affect. The recent discovery that melanopsin (Opn4) functions outside the central nervous system prompted us to explore a potential role for this receptor in blood vessel regulation. We hypothesized that Opn4-mediated signaling might explain the phenomenon of photorelaxation, for which a mechanism has remained elusive. We report the presence in blood vessels of Opn4 and demonstrate that it mediates wavelength-specific, light-dependent vascular relaxation. This photorelaxation signal transduction involves cGMP and phosphodiesterase 6, but not protein kinase G. Furthermore it is regulated by G protein-coupled receptor kinase 2 and involves vascular hyperpolarization. This receptor pathway can be harnessed for wavelength-specific light-based therapy in the treatment of diseases that involve altered vasoreactivity.

Hyperglycemia-induced reactive oxygen species (ROS) production plays a major role in the pathogenesis of diabetic vascular dysfunction. However, the underlying mechanisms remain unclear. Toll-like receptor 4 (TLR4), a key component of innate immunity, is known to be activated during diabetes. Therefore, we hypothesize that hyperglycemia activates TLR4 signaling in vascular smooth muscle cells (VSMCs) that triggers ROS production and causes vascular dysfunction. Rat mesenteric VSMCs exposed to high glucose (25 mmol/l) increased TLR4 expression and activated TLR4 signaling via upregulation of myeloid differentiation factor 88 (MyD88). TLR4 inhibitor CLI-095 significantly attenuated elevated levels of ROS and nuclear factor-kappa B (NF-κB) activity in VSMCs exposed to high glucose. Mesenteric arteries from streptozotocin-induced diabetic rats treated with CLI-095 (2 mg/kg/day) intraperitoneally for 2 weeks exhibited reduced ROS generation and attenuated noradrenaline-induced contraction. These results suggest that hyperglycemia-induced ROS generation and NF-κB activation in VSMCs are at least, in part, mediated by TLR4 signaling. Therefore, strategies to block TLR4 signaling pathways pose a promising avenue to alleviate diabetic-induced vascular complications. Key messages High glucose-induced TLR4 activation in vascular smooth muscle cells. Inhibition of TLR4 attenuated high glucose-induced ROS production and NF-κB activity in VSMC. Suppression of TLR4 signaling attenuated mesenteric contraction in diabetic rat.

Abstract Endothelial dysfunction is implicated in the thrombotic events reported in patients with coronavirus disease (COVID-19), but the underlying molecular mechanisms are unknown. Circulating levels of the coagulation cascade activator PAI-1 are substantially higher in patients with COVID-19 with severe respiratory dysfunction than in patients with bacterial sepsis and acute respiratory distress syndrome. Indeed, the elevation of PAI-1 is recognized as an early marker of endothelial dysfunction. Here, we report that the rSARS-CoV-2-S1 (recombinant severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] viral envelope spike) glycoprotein stimulated robust production of PAI-1 by human pulmonary microvascular endothelial cells (HPMECs). We examined the role of protein degradation in this SARS-CoV-2-S1 induction of PAI-1 and found that the proteasomal degradation inhibitor bortezomib inhibited SARS-CoV-2-S1–mediated changes in PAI-1. Our data further show that bortezomib upregulated KLF2, a shear-stress–regulated transcription factor that suppresses PAI-1 expression. Aging and metabolic disorders are known to increase mortality and morbidity in patients with COVID-19. We therefore examined the role of ZMPSTE24 (zinc metallopeptidase STE24), a metalloprotease with a demonstrated role in host defense against RNA viruses that is decreased in older individuals and in metabolic syndrome, in the induction of PAI-1 in HPMECs by SARS-CoV-2-S1. Indeed, overexpression of ZMPSTE24 blunted enhancement of PAI-1 production in spike protein–exposed HPMECs. In addition, we found that membrane expression of the SARS-CoV-2 entry receptor ACE2 was reduced by ZMPSTE24-mediated cleavage and shedding of the ACE2 ectodomain, leading to accumulation of ACE2 decoy fragments that may bind SARS-CoV-2. These data indicate that decreases in ZMPSTE24 with age and comorbidities may increase vulnerability to vascular endothelial injury by SARS-CoV-2 viruses and that enhanced production of endothelial PAI-1 might play role in prothrombotic events in patients with COVID-19.

Endothelial dysfunction is implicated in the thrombotic events reported in COVID-19 patients, but underlying molecular mechanisms are unknown. Circulating levels of the coagulation cascade activator PAI-1 are substantially higher in COVID-19 patients with severe respiratory dysfunction than in patients with bacterial-sepsis and ARDS. Indeed, the elevation of PAI-1 is recognized as an early marker of endothelial dysfunction. Here, we report that recombinant SARS-CoV-2-S1 stimulated robust production of PAI-1 by HPMEC. We examined the role of protein degradation in this SARS-CoV-2-S1 induction of PAI-1 and found that the proteasomal degradation inhibitor bortezomib inhibited SARS-CoV-2-S1 mediated changes in PAI-1. Our data further show that bortezomib upregulated KLF2, a shear-stress-regulated transcription factor that suppresses PAI-1 expression. Aging and metabolic disorders are known to increase the mortality and morbidity in COVID-19 patients. We therefore examined the role of ZMPSTE24, a metalloprotease with a demonstrated role in host defense against RNA viruses that is decreased in the elderly and in metabolic syndrome, in the induction of PAI-1 in HPMEC by SARS-CoV-2-S1. Indeed, overexpression of ZMPSTE24 blunted enhancement of PAI-1 production in spike protein-exposed HPMEC. Additionally, we found that membrane expression of the SARS-CoV-2 entry receptor ACE2 was reduced by ZMPSTE24-mediated cleavage and shedding of the ACE2 ectodomain, leading to accumulation of ACE2 decoy fragments that may bind SARS-CoV-2. These data indicate that decreases in ZMPSTE24 with age and comorbidities may increase vulnerability to vascular endothelial injury by SARS-CoV-2 viruses and that enhanced production of endothelial PAI-1 might play role in prothrombotic events in COVID-19 patients. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Increased levels of reactive oxygen species (ROS) are a hallmark of cardiovascular disease and are most prominently observed in blood vessels from humans and animals with diabetes, atherosclerosis and hypertension [1]. The NADPH oxidase (Nox) family of enzymes is comprised of seven members, Nox1-5 and Duox 1 and 2 [2] has been shown to be a major source of ROS including superoxide (O 2·-) and hydrogen peroxide (H2O 2) in vascular cells [3]. Nox5 was the most recent of the conventional Nox enzymes to be identified and because it has been lost from rodent genomes (mice and rats) which have become our primary models for experimentation, very little is known about the molecular regulation and functional significance of Nox5. Our first goal was to determine whether Nox5 and its splice variants α, β, δ, γ and Nox5 Short (ϵ) are expressed in human blood vessels. We detected Nox5 mRNA and protein expression in human blood vessels, smooth muscle cells and endothelial cells, but not in fibroblasts. The primary splice variants of Nox5 detected were α and β whereas δ and γ were undetected. We also found that Nox5 α and β were active and produced extracellular superoxide and H2O2, while Nox5, δ, γ and ϵ did not produce measurable ROS. As much as we lack knowledge about functional significance of Nox5, we are not so far ahead in understanding its molecular regulation. The mechanisms controlling the activity of NADPH oxidase 5 (Nox5) are unique in that they appear to be independent of the protein: protein interactions that coordinate the activation of other Nox isoforms [4]. Instead, the primary driving force for Nox5 activity is calcium [5]. While calcium is absolutely required for Nox5 activity, discrepancies between the amount of calcium needed to initiate ROS production versus that measured inside cells has led to the discovery by our laboratory and others that the calcium sensitivity of Nox5 can be modified by the specific phosphorylation of serine/threonine residues in response to the protein kinase C (PKC)-agonist, PMA resulting in a sustained activation of Nox5 at resting levels of calcium [6, 7]. However, the specific kinase(s) mediating the phosphorylation and activation of Nox5 are not known and their identification was the goal of our study. Using pharmacological inhibitors, dominant negative mutants and knockdown of endogenous genes (MEK1, MEK2 and CAMKIIα) using siRNA approach, we demonstrated that MEK1/2-ERK1/2 and CAMKIIα signaling pathways can positively regulate Nox5 activity by inducing the specific phosphorylation of S498 and S475, respectively. While much attention has been given to the mechanisms that positively regulate Nox activity, little is known about mechanisms that suppress Nox function. Cellular stress arising from changes in osmotic pressure, heat, cold etc are potent stimuli for protein SUMOylation. Importantly, oxidative stress arising from increased ROS is one of the best recognized stimuli for regulating protein SUMOylation [8, 9]. Hence, we investigated whether SUMO could influence the activity of Nox and thus limit the damaging effects of these molecules. We found that SUMO-1 and the SUMO-specific conjugating enzyme, UBC-9 potently suppressed the activity of Nox5 as well as other Nox isoforms (Nox1, 2, 3 and 4). We also found that co-expression of SUMO-1 does not result in the SUMOylation of Nox5 and that mutation of predicted sites of SUMOylation and conserved lysines on Nox5 failed to prevent the SUMO-1 driven inhibition of ROS production. In summary, we have identified the expression of Nox5 and more specifically the α and β splice variants in human blood vessels and tissues. Our data suggest that Nox5 α and β are the only variants capable of producing ROS in human blood vessels, but also that the inactive variants can function as dominant negatives. Additionally, we have shown that MAPK and CAMKIIα signaling pathways positively regulate Nox5 activity via changes in phosphorylation whereas SUMO-1 negatively regulates activity through a yet to be defined mechanism. INDEX WORDS: Nox5, siRNA, SUMO, MAPK, ERK, MEK and CAMKIIα

Gracilaria species, a widely distributed genus of red macroalgae, have gathered significant attention for their diverse medical applications attributable to their bioactive sulphated polysaccharides (SPs). This review examines the global narrative of various Gracilaria SP applications in terms of their therapeutic potential and mechanistic insights into the use of these SPs against a range of medical conditions, including cancer, inflammation, neurodegenerative disorders, diabetes, and immune dysfunctions. SPs extracted from G. lemaneiformis and G. fisheri have demonstrated potent anti-tumour activities by inducing apoptosis through various mechanisms, including the upregulation of CD8+ T cells and IL-2, inhibition of EGFR/MAPK/ERK signalling pathways, and activation of the Fas/FasL pathway. Selenium nanoparticles (SeNPs) conjugated with SPs further enhanced the targeted delivery and efficacy of these SPs against glioblastoma by the downregulation of ROS followed by the activation of p53, MAPK, and AKT pathways. The anti-inflammatory properties of SPs are evidenced by key suppressive inflammatory markers like NO, TNF-α, IL-1β, and IL-6 in mutant rodent models. SPs from G. cornea and G. birdiae effectively reduce neutrophil migration and vascular permeability, offering potential treatments for acute inflammation and conditions such as colitis by modulating pathways involving COX-2 and NF-κB. Neuroprotective effects by SPs (from G. cornea and G. gracili) studied in 6-OHDA-induced rats, which mitigate oxidative stress and enhance neuronal cell viability, facilitate the management of neurodegenerative diseases like Parkinson’s and Alzheimer’s. Regarding the hypoglycaemic effect, SPs from G. lemaneiformis exhibit a glucose-modulating response by improving insulin regulation, inhibiting α-amylase activity, repairing pancreatic β-cells, and modulating lipid metabolism. Moreover, immunomodulatory activities of Gracilaria-derived SPs include the stimulation of macrophages, T-cell proliferation, and cytokine production, underscoring their potential as functional food and immunotherapeutic agents. Recently, Gracilaria-derived SPs have been found to modulate gut microbiota, promote SCFA production, and enhance gut microbials, suggesting their potential as prebiotic agents (G. rubra and G. lemaneiformis). This review highlights the multifaceted medical applications of Gracilaria sulphated polysaccharides, providing detailed mechanistic insights and suggesting avenues for future clinical translation and therapeutic innovations.

To combat drought stress in rice, a major threat to global food security, three major quantitative trait loci for ‘yield under drought stress’ (qDTYs) were successfully exploited in the last decade. However, their molecular basis still remains unknown. To understand the role of secondary regulation by miRNA in drought stress response and their relation, if any, with the three qDTYs, the miRNA dynamics under drought stress was studied at booting stage in two drought tolerant (Sahbaghi Dhan and Vandana) and one drought sensitive (IR 20) cultivars. In total, 53 known and 40 novel differentially expressed (DE) miRNAs were identified. The primary drought responsive miRNAs were Osa-MIR2919, Osa-MIR3979, Osa-MIR159f, Osa-MIR156k, Osa-MIR528, Osa-MIR530, Osa-MIR2091, Osa-MIR531a, Osa-MIR531b as well as three novel ones. Sixty-one target genes that corresponded to 11 known and 4 novel DE miRNAs were found to be co-localized with the three qDTYs, out of the 1746 target genes identified. We could validate miRNA-mRNA expression under drought for nine known and three novel miRNAs in eight different rice genotypes showing varying degree of tolerance. From our study, Osa-MIR2919, Osa-MIR3979, Osa-MIR528, Osa-MIR2091-5p and Chr01_11911S14Astr and their target genes LOC_Os01g72000, LOC_Os01g66890, LOC_Os01g57990, LOC_Os01g56780, LOC_Os01g72834, LOC_Os01g61880 and LOC_Os01g72780 were identified as the most promising candidates for drought tolerance at booting stage. Of these, Osa-MIR2919 with 19 target genes in the qDTYs is being reported for the first time. It acts as a negative regulator of drought stress tolerance by modulating the cytokinin and brassinosteroid signalling pathway.

The accelerated rates of urbanization and increased urgency of climate change have turned the question of green and sustainable smart cities into an international priority. This work examines an interdisciplinary paradigm of health, technology, law, and business development to understand how cities may be made sustainable and resilient. The descriptive and comparative design was followed relying on the secondary data in the form of the international reports, policy documents, and case-studies related to the major smart cities in the world such as Copenhagen, Singapore, Barcelona, and Dubai. Findings indicate that those cities that allocate a greater portion of green space and take up smart healthcare, including Copenhagen (35 m 2 per capita green space, AQI 42) or Singapore (telemedicine uptake with 15% hospitalization decrease), show much better public health results. The advantages of technological integration are already measured, and a smart lighting system in Barcelona decreased the energy use by 30% and Singapore smart traffic management decreased the congestion by 25%. The areas with legal and policy frameworks (especially in Europe) enhanced the trust of citizens, and green investments amounted to USD 5.2 billion in Singapore, increasing the contribution of the green sector to GDP. The scores of comparative integration showed that Copenhagen (90/100) and Singapore (88/100) are ahead of Barcelona (80/100) and Dubai (77/100). This paper concludes that smart cities need to be developed in a holistic, cross-disciplinary manner in order to create resilient, inclusive, and prosperous cities.

In the arid region of Rajasthan, India, it is very often a challenge to store rain/surface water for year-round use by human and livestock. The inhabitants of this desert area have developed several water storage structures, which they used to construct based on their indigenous knowledge of local terrain conditions. Recently, farmers living in the lower command areas of Indira Gandhi canal have constructed micro-farm water storage structures, called diggi, in their cropland. They store allocated canal water in diggi to timely utilize it as per irrigation requirements, and thus, done away with problems of deficit and untimely canal water supply. This impact assessment study, carried out in Poogal tehsil of Bikaner district, analyzed high-resolution satellite images for 2 years and used a geographic information system to quantify diggi structures and studied the diggi-growth interactions with changing rainfall pattern as well as land use/land cover. Results showed that during 2018, about 3243 number of structures were constructed compared to 241 existed during 2004–2005. The mean annual rainfall increased by 30% and crop area by 12,772 ha during the same period that included 7.86% increase in irrigated and 2.98% in rainfed croplands. Thus, diggi-based water management has been immensely helpful in the perspective of irrigated agriculture in the desert region.